Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Moberg Pharma AB (publ) (MOB.ST)
SEK9.25
+0.08 (+0.87%)
SE STO Healthcare Drug Manufacturers - Specialty & Generic
Address
GustavslundsvAegen 42 167 51
Bromma, SE
Bromma, SE
CEO
Jonas Ekblom
Website
mobergpharma.se
IPO
2011-05-26
ISIN SE0020353928
Description
Moberg Pharma AB (publ) functions as a pharmaceutical company, dedicated to both crafting and globally marketing medical solutions throughout Europe, the United States, and various international territories. A notable product within its development portfolio is MOB-015, a treatment designed for nail fungus, which has successfully concluded its Phase III clinical trials. Established in 2006, this enterprise is headquartered in Bromma, Sweden. It was previously known as Moberg Derma AB (publ) until its rebranding to the current name in May 2013.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
SEK9.25
+0.08 (+0.87%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
114.0K
Beta
0.64
Float Shares
40.40M
Free Float %
86.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.73% | +1.85% | +9.34% | +19.96% | +12.82% | +7.42% | +45.70% | -28.25% | -68.00% | -95.34% | -93.27% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
9.25
DCF (Unlevered)
5.76
-37.8%
DCF (Levered)
2.66
-71.2%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
15.92
Safe zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
B-
Overall Score
3 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+38.0% ★ Q1'26: +27.2% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+91.4% ★ Q1'26: +54.5% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-108.4% Q1'26: -70.3% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-206.8% Q1'26: -88.9% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-6.4% Q1'26: -3.9% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+23.8% Q1'26: -2.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-0.09× Q1'26: -0.13× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
285.57M
est: 286.28M (-0.2%)
|
334.30M
est: 286.28M (+16.8%)
|
439.03M
est: 339.73M (+29.2%)
|
439.04M
est: 433.59M (+1.3%)
|
547.00M
est.
|
33.66M
est: 7.80M (+331.5%)
|
—
est: 21.00M (-100.0%)
|
207.0K
est: 39.00M (-99.5%)
|
—
est: 5.00M (-100.0%)
|
9.81M
est: 10.00M (-1.9%)
|
13.54M
est: 12.40M (+9.2%)
|
23.10M
23.10M – 23.10M
+86.3% YoY
|
56.20M
56.20M – 56.20M
+143.3% YoY
|
94.60M
94.60M – 94.60M
+68.3% YoY
|
| EBITDA |
46.44M
est: 21.40M (+117.0%)
|
83.53M
est: 21.40M (+290.3%)
|
89.44M
est: 25.40M (+252.2%)
|
-3.25M
est: 32.41M (-110.0%)
|
40.89M
est.
|
12.58M
est: 583.1K (+2,057.6%)
|
-17.15M
est: 1.57M (-1,192.2%)
|
-16.86M
est: 2.92M (-678.2%)
|
-26.96M
est: 373.8K (-7,312.4%)
|
-18.93M
est: -2.00M (-846.4%)
|
-28.00M
est: -2.48M (-1,028.9%)
|
-4.62M
-4.62M – -4.62M
-86.3% YoY
|
-11.24M
-11.24M – -11.24M
-143.3% YoY
|
-18.92M
-18.92M – -18.92M
-68.3% YoY
|
| EBIT |
35.22M
est: 17.11M (+105.8%)
|
66.34M
est: 17.11M (+287.7%)
|
51.08M
est: 20.31M (+151.5%)
|
-5.79M
est: 25.92M (-122.3%)
|
32.70M
est.
|
10.06M
est: 466.3K (+2,057.6%)
|
-19.73M
est: 1.26M (-1,671.7%)
|
-19.44M
est: 2.33M (-933.9%)
|
-27.91M
est: 298.9K (-9,438.1%)
|
-320.25M
est: -2.00M (-15,912.3%)
|
-28.00M
est: -2.48M (-1,028.9%)
|
-4.62M
-4.62M – -4.62M
-86.3% YoY
|
-11.24M
-11.24M – -11.24M
-143.3% YoY
|
-18.92M
-18.92M – -18.92M
-68.3% YoY
|
| Net Income |
25.54M
est: 152.86M (-83.3%)
|
32.67M
est: 152.86M (-78.6%)
|
11.16M
est: 204.30M (-94.5%)
|
19.84M
est: 12.76M (+55.5%)
|
80.65M
est.
|
-19.03M
est: 22.42M (-184.9%)
|
-16.22M
est: -196.21M (+91.7%)
|
-15.71M
est: -52.10M (+69.8%)
|
-21.09M
est: -30.28M (+30.3%)
|
-255.11M
est: -23.42M (-989.1%)
|
-27.24M
est: -23.42M (-16.3%)
|
-23.42M
-23.42M – -23.42M
+0.0% YoY
|
9.37M
9.37M – 9.37M
+140.0% YoY
|
37.48M
37.48M – 37.48M
+300.0% YoY
|
| SGA |
158.81M
est: 6.11B (-97.4%)
|
201.12M
est: 6.11B (-96.7%)
|
261.19M
est: 7.25B (-96.4%)
|
31.05M
est: 9.26B (-99.7%)
|
11.68B
est.
|
179.0K
est: 166.53M (-99.9%)
|
70.0K
est: 448.35M (-100.0%)
|
21.07M
est: 832.65M (-97.5%)
|
24.04M
est: 106.75M (-77.5%)
|
28.97M
est: 218.24M (-86.7%)
|
32.14M
est: 270.62M (-88.1%)
|
504.13M
504.13M – 504.13M
+86.3% YoY
|
1.23B
1.23B – 1.23B
+143.3% YoY
|
2.06B
2.06B – 2.06B
+68.3% YoY
|
| EPS |
15.37
est: 4.04 (+280.6%)
|
19.38
est: 4.04 (+379.9%)
|
5.47
est: 5.40 (+1.3%)
|
6.39
est: 0.34 (+1,795.9%)
|
2.13
est.
|
-6.51
est: 0.59 (-1,199.1%)
|
-2.43
est: -5.18 (+53.1%)
|
-1.38
est: -1.38 (-0.2%)
|
-1.33
est: -0.80 (-66.3%)
|
-6.74
est: -0.50 (-1,248.0%)
|
-0.58
est: -0.50 (-16.0%)
|
-0.50
-0.50 – -0.50
+0.0% YoY
|
0.20
0.20 – 0.20
+140.0% YoY
|
0.80
0.80 – 0.80
+300.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | B- | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-11 | B- | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-08 | B- | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-07 | B- | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-06 | B- | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-05 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-04 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-30 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-29 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-28 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-55.61M
OE per share TTM
-1.16
Owner's Yield
-10.78%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
6.1%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-28.0K
Shares Outstanding
47.00M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Anna Ljung | Chief Executive Officer | 3M | female |
| Jonas Ekblom | Executive Chairman | 312.0K | — |
| Marie Moberg | Co-Founder | 193.7K | female |
| Mark Beveridge | Vice President of Finance & CFO | — | male |
| Gunilla Wengström | Senior Director of Sales & Marketing | — | — |
| Christina Erixon | Head of Pharmaceutical Development & Operations | — | — |
| Amir Tavakkol | Chief Scientific Officer | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MOB.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
